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alive. Median serum CRP values were 23.5 (0.2-122.6) mg/l and 3.72 
(0.1-82.8) mg/l respectively (p=0.029). No correlation between CRP 
and pathologic stage of disease was found. Pretreatment Cyfra 21-1 
exceeded 3.3 ng/ml in 6/9 pts who died and 7/30 pts who were alive. 
Median Cyfra 21-1 concentrations were 5.29 (2.5-14.5) ng/ml and 1.92 
(0.7-6.2) respectively (p=0.0003). This difference was also signiﬁcant 
if only stage I and II pts were taken into analysis. 
Conclusion: Cyfra 21-1 and CRP are prognostic indicators in NSCLC 
patients treated by surgery and their inﬂuence on survival is probably 
partly independent from pathologic stage of disease. 
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Background: Intraoperative pleural lavage cytology (PLC) in patients 
with early stage of non-small cell lung cancer (NSCLCs) has been 
considered as possible aids to assess prognosis of lung cancers and was 
reported to be useful in detecting sub-clinical pleural dissemination, lo-
cal and systemic recurrence. Many studies revealed that only pre-opera-
tive PLC is necessary. We conduct a prospective study to explore any 
possible association of pre- and post-operative PCL and lymph node 
recurrence and the potential usefulness of post-operative PCL.
Methods: From December 2004 to December 2006, PLC was per-
formed before and after any manipulation or resection of the lung in 
24 consecutive patients, who had no macroscopic pleural effusion, 
dissemination, or diffuse adhesion, and who subsequently underwent 
curative resection for NSCLCs. The operations were performed by only 
one surgeon and the results of PLC with reference to clinicopathologic 
characteristics were evaluated and reported by only one pathologist. 
Tumor recurrence (local and systemic) was analyzed.
PLC consisted of cytological analysis of 50 mL of saline irrigated over 
the lung surface immediately after thoracotomy and after complete 
curative resection with radical mediastinal lymph node dissection.
Results: Nine (38%) of 24 patients had positive cytological ﬁndings. 
Positive cytological ﬁndings were observed more frequently in patients 
with adenocarcinoma, pleural involvement of the tumor and male 
gender.
Five (55%) of 9 patients had positive cytology in pre-operative PLC, 
3 (33%) in post-operative and 1 (11%) in both pre- and post-operative 
PLC. Exact McNemar signiﬁcance probability test showed no associa-
tion between pre- and post-operative cytological status (p= 0.727).
The risk of lymph nodes recurrence after 3 month of curative surgery 
in patients with negative and positive pre-operative PLC was 5.6% 
and 33.33% respectively (risk ratio = 6, 95%CI = 2 to 8, p = 0.143). In 
patients with both negative pre- and post-operative cytology, negative 
pre-operative but positive post-operative, positive pre-operative but 
negative post-operative, and positive both pre-and post-operative were 
6.7%, 0%, 20.0% and 100% respectively (p=0.123).
Conclusions: No relationship between cytological status of pleural 
lavage ﬂuid pre-operatively and post-operatively was detected. The 
study showed that if malignant cells were found in pre-operative PLC, 
the risk of lymph node recurrence in 3 months increased by 6 times, 
and maximum risk occurred when the malignant cells was found in 
both pre- and post-operative PLC. However, the increased risk was not 
statistically signiﬁcant because of the lack of statistical power due to 
small study size. If sample size were increased it may reveal that PLC 
may also be required at the time of curative resection for non-small cell 
lung cancer in order to estimate the risk of lymph node recurrence.
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Background: The primary aim of this trial was response. In both the 
control arm and in the genotypic arm with low tumor ERCC1 mRNA 
levels, p received docetaxel(doc)/cis; in the genotypic arm with high tu-
mor ERCC1 mRNA levels, p received doc/gemcitabine. Response was 
signiﬁcantly higher in the genotypic arms. We examined 324 p for ge-
netic markers that could inﬂuence response, including ERCC1 118 C/T, 
ERCC1 C8092A, XRCC3 241 (Thr to Met), Aurora A 91 T>A, Aurora 
A 169G>A, a SNP within intron 7 of the TGFBR1 gene (Int7G24A), 
and an in-frame germline deletion (TGFBR1*6A). Methylation of 14-
3-3 sigma and CHFR were also analyzed. 
Methods: DNA from peripheral lymphocytes was used for genotyp-
ing (Taqman assay) and methylation-speciﬁc PCR was used for 14-3-3 
sigma and CHFR in pretreatment serum DNA. 
Results: There were no differences in clinical characteristics among 
the different SNP types, except that p with Aurora A 91 AA had higher 
tumor ERCC1 mRNA levels (P=0.005). No relationship was found 
between ERCC1 SNPs and tumor ERCC1 mRNA levels. A strong 
correlation was found between the Int7G24A and XRCC3 241 SNPs 
(P=0.03). The Int7G24A GA type had a higher odds ratio (OR) of 
response (OR 2.32) than the AA type (OR 3.15) (P=0.02). XRCC3 241 
MetMet had a lower probability of response (OR 0.23) (P=0.04). No 
other differences in response were observed according to any of the 
other SNPs or methylation. In the multivariate model, the best response 
was observed in p with performance status (PS) 0, low ERCC1 levels, 
and XRCC3 241 SNP (Table). 
